Phaseline

Targets › ADAMTS13

ADAMTS13 (A disintegrin and metalloproteinase with thrombospondin motifs 13): drug programs, companies and trials

1 program from 1 company in 2 trials: 1 Phase 3, 1 Phase 2; Neurology, Immunology; next expected readout Mar 2027.

Cleaves the vWF multimers in plasma into smaller forms thereby controlling vWF-mediated platelet thrombus formation. (UniProt, Q76LX8)

Open in Phaseline: the race on ADAMTS13, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
TakedaApadamtase Alfa (TAK-755)
A disintegrin and metalloproteinase with thrombospondin motifs 13 exogenous protein
ADAMTS13Phase 3Thrombotic Thrombocytopenic Purpura (TTP); Acute Ischemic StrokeMar 2027

Conditions

Thrombotic Thrombocytopenic Purpura (TTP) (1) Acute Ischemic Stroke (1)

Modalities

protein or peptide (1)

Companies

Takeda (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.